Oncology

This is the first and only oncology immunotherapy to show positive phase 3 results in the adjuvant lung cancer setting.

A recent article from the American Cancer Society reports a mixed picture, with historic lows in smoking prevalence but suboptimal obesity, cancer screening, and HPV vaccination levels.

The legislation would require that patients with cancer have access to oral oncology drugs within 72 hours of having the prescription submitted to the patient’s pharmacy benefits manager.

Incidence rates of early-onset colorectal cancer in the United States have increased from 8.6 to 13.1 per 100,000 between 1992 and 2013, with most of this increase attributable to early-onset cancers of the rectum.

Other HPV-associated cancers were found to have increased over the study period, linking this trend to lack of guidelines and other resources.

Inhibiting Toll-like receptor 4 stopped it from accumulating cisplatin, thereby halting the hearing damage caused by the cancer treatment.

Selinexor in combination with bortezomib and dexamethasone is used for adult patients with multiple myeloma who have received at least 1 prior therapy.

Breast cancer patients with low or absent MLH1 or PMS2 gene expression may have even greater risks of death.

This discovery could enhance efforts to develop better treatments for breast, ovarian, and prostate cancer.

Program participants had 55% fewer hospitalizations, 45% fewer emergency department visits, and shorter hospital stays by 1 day in the 30 days after study entry.

The objective of the study was to determine whether atezolizumab could also be efficacious for patients with earlier-stage disease who may be at risk of disease recurrence following surgery

Physical changes to DNA may contribute to greater inflammation and fatigue for these individuals.

The study authors sought to examine the risks of subsequent primary cancers (SPCs) among breast cancer survivors by HR status and age at diagnosis.

In a trial of amivantamab-vmjw, investigators found an overall response rate of 40% among patients with non-small cell lung cancer whose tumors have epidermal growth factor receptor exon 20 insertion mutations.

Ssatuximab (Sarclisa, Sanofi) is used in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma.

The investigators found that using the vaccine in combination with an immune checkpoint inhibitor—an established immunotherapy drug with a 20% success rate overall for patients—can vastly improve the proportion of individuals who respond to treatments, eliminating tumors in 75% of cases in mice.

Addition of atezolizumab and durvalumab to chemotherapy is a win for patients with extensive-stage small cell lung cancer

The safety profile for the combination treatment remained consistent with previously reported data in NSCLC and was deemed manageable with established protocols with no new safety signals identified.

Median disease-free survival was twice as long in patients who received nivolumab compared to patients who received a placebo.

Locally advanced head and neck cancer represents a group of diseases that have seen few new treatment options over the past 20-plus years

The percentage dropped to only about 25% among people at a low genetic risk for the disease.

Melanoma forms when pigment-producing cells called melanocytes mutate and multiply uncontrollably.

Melphalan flufenamide (Pepaxto; melflufen) is approved for use in combination with dexamethasone to treat adult patients with relapsed or refractory multiple myeloma.

The incidence of colorectal cancer in adults between the ages of 40 and 49 years has increased by nearly 15% since 2000.

The trial found positive results in both the overall study population of patients with advanced cervical cancer as well as subgroups with squamous cell carcinoma and adenocarcinoma.

The findings contrast with those for adult BMI, which indicate that women who gain weight after menopause have an increased risk of postmenopausal breast cancer.

This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week.

The durvalumab plus chemotherapy arm demonstrated a statistically significant improvement in PFS versus chemotherapy in the previous analysis, but the OS trend observed in this analysis did not achieve statistical significance.